Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abvc Biopharma Inc (NQ: ABVC )

0.9901 -0.0599 (-5.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 168,883
Open 1.040
Bid (Size) 0.9700 (1)
Ask (Size) 1.010 (32)
Prev. Close 1.050
Today's Range 0.9651 - 1.040
52wk Range 0.6739 - 9.600
Shares Outstanding 24,420,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
FREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-17.49%
-17.49%
1 Month
-7.55%
-7.55%
3 Month
-20.79%
-20.79%
6 Month
+8.67%
+8.67%
1 Year
-84.91%
-84.91%

More News

Read More
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Via NewMediaWire
Looking Into ABVC BioPharma's Recent Short Interest
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Via NewMediaWire
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Via TheNewswire.com
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why ABVC BioPharma Stock Is Up Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Via NewMediaWire
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Via TheNewswire.com
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
Via NewMediaWire
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
Via TheNewswire.com
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Via NewMediaWire
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Via TheNewswire.com
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
Via NewMediaWire
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
Via TheNewswire.com
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
Via NewMediaWire
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
Via NewMediaWire
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.